MariMed (MariMed) Debt-to-Revenue : 0.54 (As of Mar. 2024)

View and export this data going back to 2012. Start your Free Trial

What is MariMed Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

MariMed's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $4.3 Mil. MariMed's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $78.0 Mil. MariMed's annualized Revenue for the quarter that ended in Mar. 2024 was $151.7 Mil. MariMed's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.54.

MariMed Debt-to-Revenue Historical Data

The historical data trend for MariMed's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MariMed Debt-to-Revenue Chart

MariMed Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

0.94

0.84

0.20

0.27

0.54

MariMed Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Revenue	Get a 7-Day Free Trial															0.47	0.45	0.41	0.52	0.54

Competitive Comparison of MariMed's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, MariMed's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MariMed's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, MariMed's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where MariMed's Debt-to-Revenue falls into.

MariMed Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

MariMed's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(3.878	+	76.247)	/	148.598
	=	0.54

MariMed's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(4.315	+	77.956)	/	151.732
	=	0.54

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.

MariMed Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of MariMed's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

MariMed (MariMed) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » MariMed Inc (OTCPK:MRMD) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

MRMD:Canada

Address

10 Oceana Way, Floor 2, Norwood, MA, USA, 02062

Website

https://www.marimedinc.com

MariMed Inc is a multi-state operator in the United States cannabis industry. It develops, operates, manages, and optimizes regulatory-compliant facilities for the cultivation, production, and dispensing of medical and adult-use cannabis. MariMed also licenses its proprietary brands of cannabis products along with other top brands in domestic markets Sources of revenue are comprised of Product sales (retail and wholesale), Real estate rental income, Supply procurement, Management fees, and Licensing fees.

Executives

Jon R Levine	10 percent owner	C/O MARIMED INC., 10 OCEANA WAY, NORWOOD MA 02062
Timothy Shaw	officer: Chief Operating Officer	C/O MARIMED INC, 10 OCEANA WAY, NORWOOD MA 02062
Kathleen Tucker	director	C/O 10 OCEANA WAY, 2ND FLOOR, NORWOOD MA 02062
Susan M. Villare	officer: Chief Financial Officer	C/O MARIMED INC., 10 OCEANA WAY, NORWOOD MA 02062
Selhub Eva M.d.	director	C/O MARIMED INC., 10 OCEANA WAY, NORWOOD MA 02062
David R Allen	director	C/O CONVERTED ORGANICS INC., 7A COMMERCIAL WHARF WEST, BOSTON MA 02110
Thomas Kidrin	director	11 ROYAL ROAD, BROOKLINE MA 02445
Edward J Gildea	director	C/O CONVERTED ORGANICS INC., 7A COMMERCIAL WHARF WEST, BOSTON MA 02110
Jay Coleman	director	310 EAST 46TH ST. APT 9 F, NEW YORK NY 10017
Robert N Fireman	director	145 ROSEMARY ST. SUITE H-2, NEEDHAM MA 02494
Worlds.com, Inc.	director, 10 percent owner, officer: PRESIDENT, CEO, other: TREASURER, SECRETARY	11 ROYAL ROAD, BROOKLINE MA 02445
Christopher John Ryan	officer: CFO, VICE PRESIDENT	11 ROYAL RD, BROOKLINE MA 02445